Allogeneic Transplantation after Myeloablative Rituximab/BEAM +/- Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-up Results. Biol Blood Marrow Transplant. 2019.
Immune aspects of the breast tumor microenvironment. Breast Cancer Manag. 2013;2(3):231-244..
Immune checkpoints: A therapeutic target in triple negative breast cancer. Oncoimmunology. 2014;3(3):e28325..
A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells. Cytotherapy. 2016.
Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer. 2016.
Targeting cathepsin G in myeloid leukemia. Oncoimmunology. 2013;2(4):e23442..